トランスレーショナル再生医療市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、用途別、地域別、競合別、2020-2030年

トランスレーショナル再生医療の世界市場規模は、2024年に34億2,000万米ドルとなり、2030年には62億8,000万米ドルに達すると予測され、予測期間中に10.64％の複合年間成長率（CAGR）で成長すると予測されています。

トランスレーショナル再生医療は、再生治療を通じて損傷または疾病した組織や臓器の構造や機能を回復または強化することに焦点を当てた、基礎科学研究と臨床応用の架け橋となる学際的領域を表しています。

この進化する分野は、基礎研究、前臨床試験、臨床試験、そして最終的にはヘルスケアへの統合に至るまで、医療イノベーションのパイプライン全体を包含しています。この分野は本質的に反復的であり、臨床的な洞察を研究にフィードバックすることで、治療法の選択肢を継続的に改善・拡大しています。心血管疾患、糖尿病、神経変性疾患、筋骨格系疾患などの慢性疾患の有病率の上昇と世界人口の高齢化は、先進的な再生治療に対する需要を増大させ、市場の成長を促進しています。

主な市場促進要因

再生医療における技術の進歩

主な市場課題

限られた患者アクセスと償還のハードル

地理的位置、社会経済的地位、保険の利用可能性に基づくアクセスの格差がこれらの課題をさらに複雑にしており、公平なヘルスケア提供に関する懸念が高まっています。

主要市場動向

再生治療における個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のトランスレーショナル再生医療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（細胞由来製品、遺伝子治療製品、組織工学製品）
  • 用途別（循環器科、皮膚科、糖尿病科、神経科、腫瘍科、整形外科）
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のトランスレーショナル再生医療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のトランスレーショナル再生医療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のトランスレーショナル再生医療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のトランスレーショナル再生医療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのトランスレーショナル再生医療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のトランスレーショナル再生医療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Astellas Pharma Inc.
• Athersys, Inc.
• AVITA Medical
• Axogen Corporation
• Gamida Cell Ltd.
• Integra LifeSciences Corporation
• Medtronic PLC
• Mesoblast Ltd.
• Novartis AG
• Spark Therapeutics, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Translational Regenerative Medicine Market was valued at USD 3.42 billion in 2024 and is projected to reach USD 6.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.64% over the forecast period. Translational regenerative medicine represents a multidisciplinary domain bridging fundamental scientific research and clinical application, with a focus on restoring or enhancing the structure and function of damaged or diseased tissues and organs through regenerative therapies.

This evolving field encompasses the entire medical innovation pipeline-from basic research and preclinical studies to clinical trials and eventual integration into healthcare practice. It is inherently iterative, with clinical insights feeding back into research to continually improve and expand therapeutic options. The rising prevalence of chronic conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and musculoskeletal ailments, along with an aging global population, is intensifying the demand for advanced, regenerative treatment alternatives-thereby driving market growth.

Key Market Drivers

Technological Advancements in Regenerative Medicine

Breakthrough technologies are reshaping regenerative medicine, unlocking transformative opportunities for treatment development across a spectrum of medical conditions. One notable advancement is 3D bioprinting, which enables the precise layer-by-layer construction of tissues and organs using biomaterials, living cells, and growth factors. This innovation supports the creation of tailor-made tissues and holds promise for organ transplantation and tissue regeneration.

Gene-editing technologies, particularly CRISPR-Cas9, have revolutionized the ability to modify genetic material with high precision. These tools facilitate the correction of genetic mutations, the engineering of therapeutic cells, and the development of targeted gene therapies.

Another key development is induced pluripotent stem cell (iPSC) technology, which allows adult cells to be reprogrammed into a pluripotent state. iPSCs can be differentiated into any cell type and used to create personalized cell lines for disease modeling, drug testing, and patient-specific treatments-minimizing immune rejection and enhancing clinical efficacy.

Key Market Challenges

Limited Patient Access and Reimbursement Hurdles

Access to regenerative therapies remains a significant challenge due to the high costs associated with research, development, and administration. Many treatments-such as stem cell and gene therapies-are expensive and may not be fully covered by insurance providers, who often classify these therapies as experimental or investigational. As a result, patients may face substantial out-of-pocket expenses.

The reimbursement framework for regenerative medicine is still in a developmental phase, with considerable variation across regions and healthcare systems. This inconsistency creates uncertainty for providers and patients alike. Furthermore, the regulatory approval process for regenerative therapies is often lengthy and complex, delaying patient access, particularly in urgent medical cases.

In many instances, regenerative therapies lack extensive long-term data on safety and efficacy, which can influence payer confidence and slow reimbursement decisions. Administrative requirements such as prior authorizations can also introduce delays, while healthcare providers may face operational challenges due to insufficient infrastructure or experience in managing reimbursement for advanced therapies.

Disparities in access based on geographic location, socioeconomic status, and insurance availability further compound these challenges, raising concerns about equitable healthcare delivery.

Key Market Trends

Personalized Medicine in Regenerative Therapies

Personalized medicine is emerging as a transformative trend within regenerative medicine, enabling the development of highly tailored treatments based on an individual's genetic and cellular profile. Technologies such as iPSCs derived from a patient's own cells are being used to generate specific cell types for targeted therapy. This approach reduces the risk of immune rejection and enhances therapeutic effectiveness.

Genomic data is increasingly used to guide treatment selection. Genetic testing can identify mutations or polymorphisms that impact a patient's response to certain therapies, allowing clinicians to choose the most appropriate regenerative treatment strategies.

Moreover, patient-specific disease models, developed using iPSCs, provide valuable insights into disease mechanisms, supporting the development of personalized drug regimens and regenerative protocols. Customized dosage, treatment timing, and delivery methods are optimized based on individual health profiles, which can improve therapeutic outcomes and minimize adverse effects.

In oncology, personalized regenerative approaches are driving innovation in cancer immunotherapy. Autologous therapies such as CAR-T cell therapy involve modifying a patient's own immune cells to recognize and combat cancer. These treatments are customized according to the patient's cancer subtype and genetic makeup.

Personalized medicine also emphasizes ongoing monitoring, utilizing biomarkers and genomic data to assess therapeutic response in real-time, enabling dynamic adjustments to treatment plans and ensuring optimal patient outcomes.

Key Market Players

• Astellas Pharma Inc.
• Athersys, Inc.
• AVITA Medical
• Axogen Corporation
• Gamida Cell Ltd.
• Integra LifeSciences Corporation
• Medtronic PLC
• Mesoblast Ltd.
• Novartis AG
• Spark Therapeutics Inc.

Report Scope:

In this report, the Global Translational Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Translational Regenerative Medicine Market, By Product Type:

• Cell Based Product
• Gene Therapy Product
• Tissue Engineered Product

Translational Regenerative Medicine Market, By Application:

• Cardiovascular
• Dermatology
• Diabetes
• Neurology
• Oncology
• Orthopedic

Translational Regenerative Medicine Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Translational Regenerative Medicine Market.

Available Customizations:

Global Translational Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Translational Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Cell Based Product, Gene Therapy Product, Tissue Engineered Product)
  • 5.2.2. By Application (Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Orthopedic)
  • 5.2.3. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Translational Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Translational Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. India Translational Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Translational Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Translational Regenerative Medicine Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Translational Regenerative Medicine Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application

7. Europe Translational Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Translational Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Translational Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Translational Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Translational Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Translational Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. North America Translational Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Translational Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Translational Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Translational Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application

9. South America Translational Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Translational Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Translational Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Translational Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Translational Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Translational Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Translational Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Translational Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Translational Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Astellas Pharma Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Athersys, Inc.
• 16.3. AVITA Medical
• 16.4. Axogen Corporation
• 16.5. Gamida Cell Ltd.
• 16.6. Integra LifeSciences Corporation
• 16.7. Medtronic PLC
• 16.8. Mesoblast Ltd.
• 16.9. Novartis AG
• 16.10. Spark Therapeutics, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer